Specialty Drug Management RX Form

Chat with GenHealth to automate any policy or prior auth task.


Specialty Drug Management RX

Indications

(1) Does the request meet this criterion: Must be prescribed for an FDA-approved or compendia supported indication*? 
(2) Does the request meet this criterion: FDA-Approved Indications ONLY: Must be used consistently with manufacturer’s prescribing information (e.g., contraindications, limitations, etc.)? 
(3) Does the request meet this criterion: Must be prescribed at a dose within the manufacturer’s dosing guidelines (based on diagnosis, weight, etc.) listed in the FDA approved labeling? 
(4) Does the request meet this criterion: Member must meet one of the following:? 
(5) Does the request meet this criterion: Be included within the patient population identified in the indication OR? 

YesNoN/A
YesNoN/A

Sign up to see the rest of the questions

Unlock the remaining questions and the full coverage workflow.

Sign up for free
Effective Date

NA

Last Reviewed

NA

Original Document

  Reference



Proprietary and Confidential Information of Evolent Health LLC

© 2024 Evolent Health LLC All Rights Reserved

RX.PA.033.CCH SPECIALTY DRUG MANAGEMENT The purpose of this policy is to define the prior authorization process for specialty drugs processed under the medical benefit that do not have an existing drug specific policy.
A specialty drug is any high-cost drug including injectables, infused products, oral agents, or inhaled medications, which require unique storage/ shipment and additional education and support from a health care professional. Specialty drugs offer treatment for serious, chronic, life-threatening diseases and are covered under medical benefits.

DEFINITIONS Applicable Drugs (Not All-Inclusive) J-Code Brand Generic Route of Administration Notes J1931 Aldurazyme Injection, laronidase, 0.1mg IV

J0584 Crysvita INJECTION BUROSUMAB- TWZA 1 MG Subcutaneous

J7351 Durysta bimatoprost implant IV

J1743 Elaprase Injection, idursulfase, 1mg IV

J1458 Naglazyme Injection, galsulfase, 1mg IV

A9607 Pluvicto Lutetium lu 177 vipivotide tetraxetan, therapeutic, 1 millicurie IV Radio- pharmaceutical J1300 Soliris Injection, eculizumab IV

J3241 Tepezza teprotumumab-trbw IV

J1823 Uplizna INJECTION INEBILIZUMAB-CDON 1 MG IV

J1427 Viltepso INJECTION VILTOLARSEN 10 MG IV

J1322 Vimizim Injection, elosulfase alfa, 1mg IV

TBD Nulibry Injection, fosdenopterin IV

Specialty Drugs POLICY NUMBER: RX.PA.033.CCH REVISION DATE: 02/2023 PAGE NUMBER: 2 of 3

Proprietary and Confidential Information of Evolent Health LLC
© 2024 Evolent Health LLC All Rights Reserved POLICY
It is the policy of the Health Plan to maintain a prior authorization process that promotes appropriate utilization of specific drugs with potential for misuse or limited indications. This process involves a review using Food and Drug Administration (FDA) criteria to make a determination of Medical Necessity, and approval by the Medical Policy Committee. The specialty drugs listed in this policy are subject to the prior authorization process.

PROCEDURE
Initial Authorization Criteria: Must meet all of the criteria listed below: • Must be prescribed for an FDA-approved or compendia supported indication* • FDA-Approved Indications ONLY: Must be used consistently with manufacturer’s prescribing information (e.g., contraindications, limitations, etc.) • Must be prescribed at a dose within the manufacturer’s dosing guidelines (based on diagnosis, weight, etc.) listed in the FDA approved labeling • Member must meet one of the following: o Be included within the patient population identified in the indication OR o Meet the eligibility criteria for the clinical studies

*NOTE: For indications/diagnoses that are not FDA-approved, or compendia supported, PA.252.CCH Determination of Medical Necessity will be utilized.

Reauthorization Criteria: All prior authorization renewals are reviewed on an annual basis to determine the Medical Necessity for continuation of therapy. Authorization may be extended at 1-year intervals based upon chart documentation from the prescriber that the member’s condition has improved based upon the prescriber’s assessment while on therapy.

Limitations:

If the established criteria are not met, the request is referred to a Medical Director for review, if required for the plan and level of request.

Length of Authorization (if above criteria met) Initial Authorization Up to 1 year Reauthorization Same as initial

Specialty Drugs POLICY NUMBER: RX.PA.033.CCH REVISION DATE: 02/2023 PAGE NUMBER: 3 of 3

Proprietary and Confidential Information of Evolent Health LLC
© 2024 Evolent Health LLC All Rights Reserved REFERENCES N/A

REVIEW HISTORY

DESCRIPTION OF REVIEW / REVISION DATE APPROVED Initial Review 3/22 Updated authorization durations to 1 year 2/23 Added several applicable drugs to drug table XX/XX

Record Retention
Records Retention for Evolent Health documents, regardless of medium, are provided within the Evolent Health records retention policy and as indicated in CORP.028.E Records Retention Policy and Procedure

Disclaimer
CountyCare medical payment and prior authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. The policies constitute only the reimbursement and coverage guidelines of CountyCare and its affiliated managed care entities. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies.

CountyCare reserves the right to review and update the medical payment and prior authorization guidelines in its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.

These policies are the proprietary information of Evolent Health. Any sale, copying, or dissemination of said policies is prohibited.

Book a walkthrough

Walk through this policy with us

Review how this policy can be converted into cited criteria, prior authorization checks, and operational automation.